Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Low-dose aspirin use and risk of head and neck cancer-A Danish nationwide case-control study

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Drug-drug interaction between warfarin and statins: A Danish cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Obesity-induced CYP2E1 activity in children

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Sequelae of Major Trauma Patients with Maxillofacial Fractures

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. SARS-CoV-2 in saliva, oropharyngeal and nasopharyngeal specimens

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Human papillomavirus genotype-specific risks for cervical intraepithelial lesions

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Impact of time to treatment initiation for patients with oral cavity squamous cell carcinoma: a population-based, retrospective study

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Incidence and survival of salivary gland cancer in children and young adults in Denmark: A nation-wide study for the period 1990-2015

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Results concerning a potential preventive effect of aspirin on head and neck cancer (HNC) are conflicting. We examined the association between low-dose aspirin use and HNC risk overall and by degree of human papillomavirus association in a nested case-control study using nationwide registries. Cases (n = 12 389) were all Danish residents diagnosed with primary HNC (2000-2015). Age- and sex-matched population controls (n = 185 835) were selected by risk-set-sampling. Using conditional logistic regression, we estimated multivariable-adjusted odds ratios and 95% confidence intervals for HNC associated with low-dose aspirin use (≥2 prescriptions). No association was observed between low-dose aspirin ever-use and overall HNC (odds ratio: 1.03, 95% confidence interval: 0.97-1.10). Estimates remained neutral according to patterns of use. Low-dose aspirin use appeared to slightly decrease HNC risk among the eldest (71-84 y), independently of human papillomavirus association, while slightly increase HNC risk among younger age groups (30-60, 61-70 y), driven by an increased risk of oral cancer. However, no consistent patterns in risk estimates were found according to duration and consistency of low-dose aspirin use in the age-stratified analyses.

Original languageEnglish
JournalBritish Journal of Clinical Pharmacology
Volume87
Issue number3
Pages (from-to)1561-1567
Number of pages7
ISSN0306-5251
DOIs
Publication statusPublished - Mar 2021

    Research areas

  • aspirin, head and neck neoplasms, human papilloma virus, nonsteroidal anti-inflammatory agents, pharmacoepidemiology

ID: 60788825